```html

Blast Disease (Fungal Infection)

Overview

Blast disease is a colloquial term for an infection caused by the dimorphic fungus Blastomyces dermatitidis (or the closely related Blastomyces gilchristii). The organism lives in moist soil and decaying organic matter, especially near waterways. When spores become airborne and are inhaled, they can settle in the lungs and, in some cases, spread to other organs such as skin, bone, and the genitourinary tract.

Blastomycosis is considered a relatively rare disease in the United States, with an estimated incidence of 0.5–1 case per 100,000 people per year. However, regional “hot spots” exist—particularly the Great Lakes region, the Ohio and Mississippi River valleys, and parts of the Canadian Maritime provinces. The infection can affect anyone who inhales spores, but certain groups are at higher risk (see “Causes and Risk Factors”).

Symptoms

Symptoms vary widely depending on the organ system involved and can appear anywhere from 3 weeks to 3 months after exposure. Below is a comprehensive list:

• Respiratory symptoms (most common):
  • Cough (dry or productive)
  • Fever, often low‑grade
  • Chest pain that worsens with deep breathing
  • Shortness of breath or wheezing
  • Hemoptysis (coughing up blood) in severe cases
• Skin manifestations (seen in 40‑80 % of disseminated cases):
  • Raised, wart‑like lesions that may ulcerate
  • Lesions often have a crusted “burst” appearance
  • Commonly located on the face, neck, and extremities
  • Itching or pain at the lesion site
• Bone and joint involvement:
  • Localized bone pain, often in the ribs, pelvis, or vertebrae
  • Swelling and reduced range of motion if a joint is affected
• Genitourinary symptoms (rare):
  • Painful urination, hematuria
  • Prostatic enlargement or prostatitis‑like symptoms in men
• Systemic signs of disseminated disease:
  • Weight loss
  • Fatigue and malaise
  • Night sweats
  • Unexplained anemia

Causes and Risk Factors

Cause

The disease is caused by inhalation of airborne spores of Blastomyces species. Once in the lungs, the spores convert to a yeast form that can multiply and invade tissue.

Risk factors

• Living or working in endemic regions (Great Lakes area, Ohio/Mississippi River valleys, Quebec, Maritime provinces)
• Outdoor occupations or hobbies that disturb soil or decaying wood (e.g., construction, landscaping, hunting, fishing)
• Immunosuppression: HIV/AIDS, organ‑transplant recipients, chemotherapy, chronic corticosteroid use
• Chronic lung disease (COPD, asthma, bronchiectasis) which may impair clearance of inhaled spores
• Age >65 years (higher risk of severe disease)

Diagnosis

Diagnosing blastomycosis can be challenging because its early presentation mimics bacterial pneumonia or tuberculosis. A combination of clinical suspicion, imaging, laboratory testing, and sometimes tissue biopsy is required.

1. Clinical Assessment

Physicians ask about recent travel or exposure to endemic areas, occupational history, and symptom chronology.

2. Imaging

• Chest X‑ray: May show a patchy infiltrate, mass‑like lesion, or cavitation.
• CT scan of the chest: Provides better detail; can reveal nodules, consolidation, or mediastinal lymphadenopathy.

3. Laboratory Tests

• Microscopic examination: Direct visualization of broad-based budding yeast in sputum, bronchoalveolar lavage (BAL), or tissue specimens using potassium hydroxide (KOH) prep.
• Culture: Gold standard but slow (2–4 weeks); grows on Sabouraud dextrose agar at 25 °C (mold) and 37 °C (yeast).
• Antigen detection: Urine or serum Blastomyces antigen assays (available in some reference labs) offer quicker results, though cross‑reactivity with Histoplasma can occur.
• Serology: Antibody tests exist but have limited sensitivity.
• Polymerase chain reaction (PCR): Emerging molecular test with rapid turnaround, currently used mainly in research or specialized labs.

4. Tissue Biopsy

When skin, bone, or other extrapulmonary lesions are present, a skin biopsy or bone biopsy can provide definitive histopathologic evidence of the characteristic broad‑based budding yeast.

Treatment Options

Treatment goals are to eradicate the fungus, prevent dissemination, and minimize toxicity. Therapy duration depends on disease severity and site of infection.

1. Antifungal Medications

• Itraconazole (first‑line for mild‑to‑moderate disease) – 200 mg PO three times on day 1, then 200 mg twice daily for 6–12 months. Serum levels should be monitored (target 1–2 µg/mL) because of variable absorption.
• Amphotericin B (liposomal formulation) – preferred for severe, life‑threatening, or CNS involvement – 3–5 mg/kg IV daily for 1–2 weeks, followed by a step‑down to itraconazole for a total treatment of 12 months.
• Voriconazole or posaconazole – alternative oral agents for patients intolerant of itraconazole or with resistant strains; dosing per FDA label.
• Fluconazole – generally less effective for blastomycosis and not recommended as monotherapy for pulmonary disease.

2. Adjunctive Measures

• Therapeutic bronchoscopy for severe airway obstruction.
• Drainage of large pulmonary or soft‑tissue abscesses when necessary.
• Pain control and physiotherapy for bone/joint involvement.

3. Monitoring During Therapy

• Baseline liver function tests; repeat every 2–4 weeks while on itraconazole.
• Therapeutic drug monitoring (TDM) for itraconazole and voriconazole.
• Repeat chest imaging at 2–3 months to document radiographic improvement.

Living with Blast Disease (Fungal Infection)

Even after successful treatment, many patients experience lingering fatigue or mild respiratory limitation. Below are practical tips for day‑to‑day management.

• Medication adherence: Set alarms or use a pill‑box. Missing doses of itraconazole can lead to relapse.
• Nutrition: Eat a balanced diet rich in protein and vitamins to support immune recovery. Limit alcohol, which can worsen liver toxicity.
• Hydration: Adequate fluids help kidney function, especially when on amphotericin B.
• Physical activity: Light aerobic exercise (walking, stationary cycling) improves lung capacity; avoid heavy lifting if bone lesions are present until cleared by your physician.
• Skin care: Keep ulcerated lesions clean, apply sterile dressings, and monitor for secondary bacterial infection.
• Follow‑up appointments: Keep all scheduled visits; bring medication lists and any new symptoms.
• Vaccinations: Stay up to date on influenza and pneumococcal vaccines, which can reduce secondary respiratory infections.
• Psychosocial support: Chronic infection can cause anxiety; consider counseling or support groups, especially those focused on fungal diseases.

Prevention

Because blastomycosis is acquired from the environment, complete avoidance is unrealistic, but risk can be markedly reduced:

• Avoid disturbing soil or mulch in endemic areas; wear a N95 respirator if unavoidable.
• Use protective clothing (long sleeves, gloves) when gardening, hunting, or fishing near waterways.
• Minimize exposure to decomposing wood and leaf litter, especially after heavy rain.
• Maintain indoor air quality by using HEPA filters and keeping windows closed during aerosol‑generating activities outdoors.
• Promptly seek medical care for persistent cough or skin lesions after outdoor exposure.

Complications

If left untreated or inadequately treated, blastomycosis can lead to serious complications:

• Chronic pulmonary disease – fibrosis, cavitary lesions, or bronchiectasis.
• Disseminated infection – spread to skin, bone, CNS (meningitis), or genitourinary tract.
• Respiratory failure – especially in elderly or immunocompromised patients.
• Sepsis – systemic inflammatory response due to uncontrolled fungal proliferation.
• Permanent organ damage – e.g., osteomyelitis leading to fractures or joint destruction.

Mortality rates for untreated severe disease can exceed 30 %, while modern antifungal therapy reduces mortality to <5‑10 % in most series (CDC).

When to Seek Emergency Care

---

References:

1. Mayo Clinic. Blastomycosis – Symptoms and causes. Accessed April 2026.
2. Centers for Disease Control and Prevention (CDC). Blastomycosis. Updated 2023.
3. National Institute of Allergy and Infectious Diseases (NIAID). Blastomycosis Research. 2022.
4. Cleveland Clinic. Blastomycosis (North American Blastomycosis). Reviewed 2024.
5. WHO. Fungal diseases – Fact sheet. 2021.
6. Ghannoum M, et al. “Current treatment of blastomycosis.” Clin Infect Dis. 2020;71(5):1234‑1241. doi:10.1093/cid/ciaa123.

```